4 recruiting, 1 completed, 1 unknown. 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 4, Completed 1, Unknown 1 |
Follow Myelosuppression: new trials by email Literature Review of Myelosuppression trials Research Report on Myelosuppression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) Trilaciclib and Sacituzumab Tirumotecan - NSCLC (Advanced Non-small Cell Lung Cancer), EGFR | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 49 | 2025-12-08 | 2026-04-14 |
| Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy Mecapegfilgrastim injection, Oral or short-acting granulocyte-stimulating agents - Myelosuppression, Thoracic Neoplasms | Phase 2 | Recruiting | Affiliated Hospital of Nantong University | 30 | 2025-08-01 | 2025-12-11 |
| Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC Trilaciclib combined with Docetaxel - Non-Small Cell Lung Cancer, Myelosuppression | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 33 | 2025-05-09 | 2025-06-08 |
| A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib Chemotherapy, Trilaciclib Injection [Cosela] - Ewing Sarcoma, Myelosuppression | Phase 2 | Recruiting | Fudan University | 22 | 2024-10-31 | 2024-11-21 |
| Trilaciclib Prevents Myelosuppression With Chemoradiotherapy Trilaciclib - Myelosuppression | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 40 | 2024-06-26 | 2024-09-24 |
| Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia Myelo001, Placebo - Chemotherapy-Induced Neutropenia, Myelosuppression | Phase 2 | Completed | Myelo Therapeutics GmbH | 137 | 2016-03-01 | 2017-11-24 |
Carcinoma, Non-Small-Cell Lung (2) · Breast Neoplasms (1) · Febrile Neutropenia (1) · Neutropenia (1) · Sarcoma, Ewing (1) · Thoracic Neoplasms (1)
Neoplasms (5) · Neoplasms by Site (4) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Lung Neoplasms (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Agranulocytosis (1) · Breast Diseases (1) · Cytopenia (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Leukocyte Disorders (1)
trilaciclib (3) · Chemoradiotherapy (1) · Docetaxel (1) · Drug Therapy (1) · pegylated granulocyte colony-stimulating factor (1)
The First Affiliated Hospital of Xiamen University (2) · Affiliated Hospital of Nantong University (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Fudan University (1) · Myelo Therapeutics GmbH (1)
China (5) · Germany (1)
Dirk Pleimes, MD (1) · Lei Deng, PhD (1)
2015 (1)